Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

Getting the Right Diagnosis and Ruling Out Other Diseases

At a Glance

Systemic JIA is diagnosed from the overall pattern rather than one definitive test, and joint swelling may appear later. Doctors track daily fever and fleeting rash while using blood tests and imaging to rule out infection, leukemia, Kawasaki disease, MIS-C, and other serious conditions.

The path to a systemic juvenile idiopathic arthritis (sJIA) diagnosis is often described as an “odyssey” because there is no single test that can provide a “yes” or “no” answer [1]. Instead, doctors must play the role of a detective, carefully ruling out other serious illnesses while checking for a specific pattern of symptoms.

The Diagnostic Framework

To formally classify a child with sJIA for research and standardization, rheumatologists often use the ILAR criteria (International League of Associations for Rheumatology) [2]. These classification criteria act as a checklist to ensure populations studied are uniform:

  • Age: The child must be under 16 years old at the start of symptoms [2].
  • Fever: A fever that has lasted at least 2 weeks and has been “daily” (peaking once a day and returning to normal) for at least 3 days [2].
  • Arthritis: Swelling, pain, or limited movement in at least one joint that lasts for 6 weeks [2].
  • One More Sign: At least one of the following: a fleeting pink rash, enlarged lymph nodes, an enlarged liver or spleen, or inflammation of the lining around the heart or lungs (serositis) [2][3].

Importantly, these are classification criteria, not rigid rules that delay treatment. The biggest frustration for parents is that sJIA rarely follows the “rules” right away. In fact, research shows that up to 50% of children eventually diagnosed with sJIA do not meet the full ILAR criteria at first [4].

The main reason for this is arthritis. While the fever and rash often show up first, joint swelling might not appear for weeks or even months [5]. About 17% to 21% of children do not have any joint swelling when they are first seen by a doctor [5][6]. Because the formal criteria require arthritis, your doctor may use terms like “probable sJIA” while they continue to monitor your child’s joints [7]. This allows them to begin urgent treatment while remaining vigilant.

Ruling Out the “Mimics”

Because the symptoms of sJIA—fever, rash, and high inflammation—look like many other things, doctors must rule out several “mimics” before they can be certain [1]:

  • Infections: Serious bacterial infections or sepsis can cause high fevers and rashes [8].
  • Leukemia: Some childhood cancers, specifically leukemia, can cause bone pain, fever, and changes in blood counts that look very similar to early sJIA [9][1].
  • Kawasaki Disease: This inflammatory condition also features high fevers and rashes but requires different treatment to protect the heart [10][11].
  • MIS-C: A condition related to COVID-19 that causes intense whole-body inflammation [11][12].

Key Laboratory “Clues”

While no blood test is definitive, certain markers help point the way toward sJIA and away from its mimics:

  • Ferritin: This protein is often elevated in sJIA, especially if a complication like Macrophage Activation Syndrome (MAS) is developing [13]. While other conditions like Kawasaki disease can elevate ferritin, sJIA levels can be much higher, though levels overlap substantially and a high ferritin alone cannot distinguish them [13][14].
  • Complete Blood Count (CBC): In early sJIA, doctors often see a very high white blood cell count (specifically neutrophils) [8]. If the blood counts show a sudden drop in platelets or red blood cells, it can be a warning sign for MAS or a reason to look closer for leukemia [15][12].
  • S100 Proteins (Calprotectin): These are specialized biomarkers that may sometimes be used in specialist settings to provide clues, as they can be significantly higher in children with sJIA than in those with leukemia or other forms of arthritis, though they are not universally available stand-alone tests [9][16]. Testing for calprotectin (S100A8/A9) can help your doctor feel more confident in an sJIA diagnosis when arthritis is not yet present [9].

Why It Takes Time

It is normal for this process to require multiple rounds of blood work, imaging (like ultrasounds or echocardiograms), and, when clinically indicated by the complete clinical picture, bone marrow tests [17][18]. This isn’t because your doctors are “clueless”; it’s because they are being thorough. Ruling out a serious infection or cancer is the most important first step to ensuring your child gets the right treatment for sJIA safely [1]. Your patience during this “ruling out” phase is vital to your child’s long-term health.

Common questions in this guide

Can a child have sJIA without joint swelling at first?
Yes. Fever and the fleeting rash may appear weeks or months before obvious arthritis, so some children do not have joint swelling at the first visit. Doctors may describe the diagnosis as probable sJIA and examine the joints repeatedly while ruling out other causes.
What conditions are doctors trying to rule out before confirming sJIA?
Doctors may evaluate for serious infections or sepsis, leukemia, Kawasaki disease, and multisystem inflammatory syndrome in children, also called MIS-C. These conditions can cause fever, rash, and abnormal inflammation but require different treatment.
What do ferritin and a complete blood count show in suspected sJIA?
Ferritin is often high in sJIA and may rise further when a serious complication called macrophage activation syndrome is developing, but a high result alone cannot confirm sJIA. A complete blood count may show many white blood cells early on; falling platelets or red blood cells can prompt evaluation for macrophage activation syndrome or leukemia.
Can a calprotectin or S100 test confirm systemic JIA?
No single blood test confirms systemic JIA. S100 proteins, including calprotectin, may provide extra clues in specialist settings and may be helpful when arthritis is not yet visible, but results must be interpreted with the examination and other tests.
Why might my child need repeated tests or a bone marrow test?
Symptoms and blood results can change as the illness evolves, so doctors may repeat blood work and imaging such as an ultrasound or echocardiogram. A bone marrow test may be considered when the complete clinical picture calls for it, including to investigate another cause such as leukemia.
What should I track while doctors are evaluating my child?
Record when the fever spikes, whether it follows a daily pattern, and whether the rash appears with the fever and fades afterward. Also note new joint swelling or limited movement, bone or muscle pain, and unusual bruising, then share these observations with the care team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My child has the classic sJIA fever and rash, but no joint swelling yet—is this why the diagnosis is still considered 'probable' rather than 'confirmed'?
  2. 2.What specific infections or malignancies (like leukemia) are you ruling out right now, and what tests are being used to do that?
  3. 3.How are my child's ferritin levels and platelet counts trending compared to their baseline?
  4. 4.Would testing for specific biomarkers like IL-18 or S100 proteins (calprotectin) be helpful in our case to distinguish this from other conditions?
  5. 5.If we are suspecting sJIA but don't see arthritis, how often should my child be re-examined for subtle joint changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Systemic Juvenile Idiopathic Arthritis.

    Lee JJY, Schneider R

    Pediatric clinics of North America 2018; (65(4)):691-709 doi:10.1016/j.pcl.2018.04.005.

    PMID: 30031494
  2. 2

    Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis.

    Jain D, Aggarwal HK, Rao A, et al.

    Reumatologia 2016; (54(1)):42-7 doi:10.5114/reum.2016.58763.

    PMID: 27407277
  3. 3

    Juvenile Idiopathic Arthritis.

    Sudhakar M, Kumar S

    Indian journal of pediatrics 2024; (91(9)):949-958 doi:10.1007/s12098-023-04939-5.

    PMID: 38163829
  4. 4

    Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.

    Hinze CH, Holzinger D, Lainka E, et al.

    Pediatric rheumatology online journal 2018; (16(1)):7 doi:10.1186/s12969-018-0224-2.

    PMID: 29357887
  5. 5

    Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.

    Baris HE, Anderson E, Sozeri B, Dedeoglu F

    Clinical rheumatology 2018; (37(12)):3263-3273 doi:10.1007/s10067-018-4297-6.

    PMID: 30238379
  6. 6

    Systemic onset juvenile idiopathic arthritis: a single center experience.

    Sağ E, Uzunoğlu B, Bal F, et al.

    The Turkish journal of pediatrics 2019; (61(6)):852-858.

    PMID: 32134578
  7. 7

    Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis.

    Gohar F, McArdle A, Jones M, et al.

    Annals of the rheumatic diseases 2019; (78(8)):1107-1113 doi:10.1136/annrheumdis-2019-215051.

    PMID: 31005900
  8. 8

    Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.

    Ter Haar NM, Tak T, Mokry M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2018; (70(6)):943-956 doi:10.1002/art.40442.

    PMID: 29426067
  9. 9

    A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings.

    Foell D, Saers M, Park C, et al.

    Molecular and cellular pediatrics 2023; (10(1)):14 doi:10.1186/s40348-023-00168-0.

    PMID: 37878193
  10. 10

    Overlapping clinical features of systemic juvenile idiopathic arthritis and SARS-CoV-2-related multisystem inflammatory syndrome in children.

    Boyarchuk O, Kovalchuk T

    Reumatologia 2023; (61(1)):63-70 doi:10.5114/reum/161185.

    PMID: 36998579
  11. 11

    Kawasaki Disease-Associated Cytokine Storm Syndrome.

    Tsoukas P, Yeung RSM

    Advances in experimental medicine and biology 2024; (1448()):365-383 doi:10.1007/978-3-031-59815-9_25.

    PMID: 39117827
  12. 12

    Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children.

    Aydın F, Çelikel E, Ekici Tekin Z, et al.

    International journal of rheumatic diseases 2021; (24(4)):542-547 doi:10.1111/1756-185X.14078.

    PMID: 33550678
  13. 13

    Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.

    Otar Yener G, Paç Kısaarslan A, Ulu K, et al.

    Rheumatology international 2022; (42(5)):879-889 doi:10.1007/s00296-021-04980-7.

    PMID: 34491393
  14. 14

    Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease.

    Mizuta M, Shimizu M, Inoue N, et al.

    Modern rheumatology 2016; (26(6)):929-932 doi:10.3109/14397595.2016.1159120.

    PMID: 27433933
  15. 15

    Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.

    Huang S, Liu Y, Yan W, et al.

    Pediatric rheumatology online journal 2024; (22(1)):58 doi:10.1186/s12969-024-00991-3.

    PMID: 38783316
  16. 16

    MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.

    Park C, Miranda-Garcia M, Berendes R, et al.

    Rheumatology (Oxford, England) 2022; (61(7)):3082-3092 doi:10.1093/rheumatology/keab729.

    PMID: 34559193
  17. 17

    Diagnostic value of basic and extended procedures in pediatric fever of unknown origin - results of a nation-wide surveillance study.

    Bienioschek MK, Lejeune A, Ngoumou G, et al.

    Molecular and cellular pediatrics 2026; (13(1)).

    PMID: 42377852
  18. 18

    Therapeutic plasma exchange in refractory macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a case-based review.

    Liquidano-Perez E, Maza-Ramos G, Salazar-Bailón JL, et al.

    Rheumatology international 2023; (43(1)):183-189 doi:10.1007/s00296-022-05231-z.

    PMID: 36264324

This page explains how clinicians evaluate suspected systemic JIA and rule out infections, leukemia, and other conditions for educational purposes only; it does not replace medical advice. Your child’s care team should interpret test results and guide next steps.

Get notified when new evidence is published on Systemic-onset juvenile idiopathic arthritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.